Update on a Promising New Drug to Treat JM: Vamorolone
Cure JM is making extraordinary progress in juvenile myositis research, including a partnership with ReveraGen Biotech to advance the drug vamorolone toward a clinical trial in JM.
Cure JM is making extraordinary progress in juvenile myositis research, including a partnership with ReveraGen Biotech to advance the drug vamorolone toward a clinical trial in JM.
1. What is Cabaletta’s RESET Myositis trial? RESET-Myositis is a phase 1/2 clinical trial being conducted to evaluate the effects of the investigational cell treatment
The Spring Cure JM Medical Symposium in partnership with Duke University happened May 23rd, 2024, virtually, with presentations from world-leading researchers and clinicians on advancements in basic research, translational studies, and best practice clinical care in juvenile dermatomyositis.
Membership is free and we’ll connect you with a network of support, encouragement, and resources.
To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.